EP1140144A4 - Procedes et composition de melanges naturels extremement purifies d'interferons de type i derives des leucocytes - Google Patents

Procedes et composition de melanges naturels extremement purifies d'interferons de type i derives des leucocytes

Info

Publication number
EP1140144A4
EP1140144A4 EP99967753A EP99967753A EP1140144A4 EP 1140144 A4 EP1140144 A4 EP 1140144A4 EP 99967753 A EP99967753 A EP 99967753A EP 99967753 A EP99967753 A EP 99967753A EP 1140144 A4 EP1140144 A4 EP 1140144A4
Authority
EP
European Patent Office
Prior art keywords
leukocytes
composition
methods
type
highly purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99967753A
Other languages
German (de)
English (en)
Other versions
EP1140144A2 (fr
Inventor
Joseph P Morris
Duy Nguyen
James Kappelman
Mead M Mccabe
Michael D Potter
M Reza Ziai
Stephen Feldman
Hipolito Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viragen Inc
Original Assignee
Viragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/224,895 external-priority patent/US6350589B1/en
Priority claimed from US09/229,039 external-priority patent/US6433144B1/en
Application filed by Viragen Inc filed Critical Viragen Inc
Publication of EP1140144A2 publication Critical patent/EP1140144A2/fr
Publication of EP1140144A4 publication Critical patent/EP1140144A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP99967753A 1998-12-31 1999-12-29 Procedes et composition de melanges naturels extremement purifies d'interferons de type i derives des leucocytes Withdrawn EP1140144A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US224895 1998-12-31
US09/224,895 US6350589B1 (en) 1998-12-31 1998-12-31 Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US09/229,039 US6433144B1 (en) 1999-01-12 1999-01-12 Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US229039 1999-01-12
PCT/US1999/031198 WO2000039280A2 (fr) 1998-12-31 1999-12-29 Procedes et composition de melanges naturels extremement purifies d'interferons de type i derives des leucocytes

Publications (2)

Publication Number Publication Date
EP1140144A2 EP1140144A2 (fr) 2001-10-10
EP1140144A4 true EP1140144A4 (fr) 2002-10-30

Family

ID=26919102

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967753A Withdrawn EP1140144A4 (fr) 1998-12-31 1999-12-29 Procedes et composition de melanges naturels extremement purifies d'interferons de type i derives des leucocytes

Country Status (2)

Country Link
EP (1) EP1140144A4 (fr)
WO (1) WO2000039280A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155730A0 (en) 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
FR2822845B1 (fr) 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
FR2825716B1 (fr) 2001-06-11 2004-09-24 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2006212012B2 (en) 2005-02-12 2011-10-13 Swedish Orphan Biovitrum International Ab Methods and uses of antibodies in the purification of interferon
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (fr) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Système de libération osmotique avec ensemble de piston
WO2008133908A2 (fr) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Formulations en suspension de peptides insulinotropes et leurs utilisations
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
WO1993016107A1 (fr) * 1992-02-10 1993-08-19 Interferon Sciences, Inc. Composition amelioree d'alpha interferon et procede de preparation a partir de leucocytes peripheriques humains
EP0626448A2 (fr) * 1993-05-26 1994-11-30 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Procédé de la préparation et de purification d'interféron-alpha
EP0679718A2 (fr) * 1994-04-09 1995-11-02 F. Hoffmann-La Roche AG Procédé pour la production d'interferon-alpha

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
WO1993016107A1 (fr) * 1992-02-10 1993-08-19 Interferon Sciences, Inc. Composition amelioree d'alpha interferon et procede de preparation a partir de leucocytes peripheriques humains
EP0626448A2 (fr) * 1993-05-26 1994-11-30 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Procédé de la préparation et de purification d'interféron-alpha
EP0679718A2 (fr) * 1994-04-09 1995-11-02 F. Hoffmann-La Roche AG Procédé pour la production d'interferon-alpha

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KANDEFER-SZERSZEN MARTYNA ET AL: "Influence of the perinatal period on bovine interferon production.", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, vol. 42, no. 4, 1994, pages 307 - 311, XP001088148, ISSN: 0004-069X *
MULLICK ASHIM ET AL: "Comparison of fluoride modified zirconia with ceramic hydroxyapatite for preparative scale purification of immunoglobulin from serum albumin.", PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, vol. 28, no. 1, February 1998 (1998-02-01), pages 1 - 21, XP001088247, ISSN: 1082-6068 *
See also references of WO0039280A3 *
SHIRONO H ET AL: "STUDIES ON SUBTYPE COMPOSITION IN NATURAL LEUKOCYTE INTERFERON PREPARATIONS", JOURNAL OF VIROLOGICAL METHODS, vol. 27, no. 1, 1990, pages 1 - 10, XP001087823, ISSN: 0166-0934 *
SHIRONO H ET AL: "STUDY ON SUBTYPE COMPOSITION OF PURIFIED HUMAN LEUKOCYTE INTERFERON FOR CLINICAL USE", JOURNAL OF INTERFERON RESEARCH, vol. 8, no. SUPPL. 1, 1988, pages S62, XP001084337, ISSN: 0197-8357 *
SHIRONO HIROYUKI ET AL: "Identification of Glycosylated Subtypes of Interferon-alpha Produced by Human Leukocytes.", BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 58, no. 9, 1994, pages 1714 - 1715, XP001087825, ISSN: 0916-8451 *

Also Published As

Publication number Publication date
EP1140144A2 (fr) 2001-10-10
WO2000039280A8 (fr) 2000-10-19
WO2000039280A3 (fr) 2001-07-19
WO2000039280A2 (fr) 2000-07-06

Similar Documents

Publication Publication Date Title
EP1140144A4 (fr) Procedes et composition de melanges naturels extremement purifies d'interferons de type i derives des leucocytes
PL320251A1 (en) Interferon conjugates, method of obtaining and pharmaceutic compositions containing them
PL341798A1 (en) Cogarette of reduced sideward smoke flow
IL141403A0 (en) Deleted adenoviruses and methods of making and administering the same
PL324558A1 (en) Extract from iridaceae and compositions containing same
PL332415A1 (en) Ore cleaning compositions and methods
BG103914A (en) Maintained separation of delayed gels
AU1159897A (en) Analogs of peptide yy and uses thereof
EP0777473A4 (fr) Compositions et procedes visant a reduire l'usage du tabac
PL331423A1 (en) Muporocin and chlorohexidrin containing compositions
ZA959907B (en) Iminooxymethyleneanilides preparation thereof and intermediates therefor and compositions containing them
HUP9904332A3 (en) Compositions and articles of manufacture
ZA9710934B (en) Compositions and methods for administering pneumococal dna
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
EP1139981A4 (fr) Compositions et procedes d'utilisation associes
GB9409944D0 (en) New compositions of matter
AU6407300A (en) Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods
GB9405234D0 (en) New compositions of matter
NZ277605A (en) Human stanniocalcin-alpha polypeptide and dna (rna) encoding polypeptide; polypeptide may be derived from atcc 75861
GB9612990D0 (en) Compositions and methods for the treatment of chronic infections
PL348162A1 (en) Methods of conversion of interferon isoforms and products thereof
EP0929540A4 (fr) Compositions antitumorales et methodes therapeutiques
HUP0104761A3 (en) Modification of interferon alpha production
EP1011662A4 (fr) Compositions et methodes ameliorees pour la lutte contre le tabagisme
TW323453U (en) Improved structure of necktie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010726

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HARTMAN, HIPOLITO

Inventor name: FELDMAN, STEPHEN

Inventor name: ZIAI, M., REZA

Inventor name: POTTER, MICHAEL, D.

Inventor name: MCCABE, MEAD, M.

Inventor name: KAPPELMAN, JAMES

Inventor name: NGUYEN, DUY

Inventor name: MORRIS, JOSEPH, P.

R17D Deferred search report published (corrected)

Effective date: 20010823

A4 Supplementary search report drawn up and despatched

Effective date: 20020911

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040820

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060601